Short answer
ArriVent BioPharma, Inc. (AVBP) filed an 8-K current report with the SEC on March 17, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events). Firmonertinib (EGFR inhibitor) and ARR-002 (MUC16/NaPi2b tetravalent ADC) preclinical data to be presented at 2026 AACR Annual Meeting.
ArriVent BioPharma, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Firmonertinib (EGFR inhibitor) and ARR-002 (MUC16/NaPi2b tetravalent ADC) preclinical data to be presented at 2026 AACR Annual Meeting
- ARR-002 is a novel dual-target ADC: early pipeline asset; AACR presentation marks first public preclinical data disclosure
- EGFR inhibitor firmonertinib poster signals continued pipeline advancement in a competitive but validated oncology target class
Item 8.01 · Other Events
- ArriVent BioPharma (AVBP) issued a press release containing material information disclosed under Item 8.01
- Full details available in the referenced exhibit: filing text itself contains no disclosed figures or event specifics
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ArriVent BioPharma, Inc. 8-K filings
Get the next AVBP 8-K as it lands
Follow AVBP for push alerts, or ask the research agent what this filing means.